18:08 , Feb 28, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Parkinson’s disease (PD) Rat studies suggest non-catechol-based dopamine D1 receptor agonists could help treat PD more effectively than catechol-based agonists. High throughput screening of about 3 million compounds in an...
07:00 , May 11, 2015 |  BC Week In Review  |  Clinical News

Ropinirole: Phase III started

Hisamitsu began a double-blind, Japanese Phase III trial of once-daily transdermal HP-3000 in patients receiving L-dopa. Patients will receive HP-3000 plus an oral placebo; once-daily oral ropinirole extended release plus a transdermal placebo; or a...
08:00 , Feb 17, 2014 |  BC Week In Review  |  Clinical News

Ropinirole: Phase II data

A placebo-controlled, Japanese Phase II trial in PD patients showed that once-daily HP-3000 used concomitantly with levodopa met the primary efficacy endpoint. No adverse events were reported "that would cause major concerns in development." Hisamitsu...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Clinical News

Ropinirole: Phase II started

Hisamitsu began a placebo-controlled, Japanese Phase II trial to evaluate once-daily HP-3000 in patients with moderate to severe idiopathic RLS. Hisamitsu plans to start a Phase III trial of HP-3000 for the fiscal year 2015...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

SmithKline regulatory update

The FDA granted marketing approval for Requip ropinirole to treat the signs and symptoms of Parkinson's disease. The product can be used as an initial therapy and as adjunctive treatment with levodopa, the standard treatment....
07:00 , Jul 16, 2012 |  BC Week In Review  |  Clinical News

Titan preclinical data

In a non-human primate model of PD, Titan's subcutaneous ropinirole implant significantly reduced clinical symptoms of PD over several months as measured by Unified Parkinson's Disease Rating Scale (UPDRS) scores vs. controls. Titan also said...
07:00 , May 7, 2012 |  BioCentury  |  Strategy

Jazz's big band sound

A 2008 decision to concentrate on its commercial business has paid off for Jazz Pharmaceuticals Inc. The company has quadrupled its revenues, reduced its debt and increased its number of marketed drugs tenfold with two...
07:00 , May 23, 2011 |  BioCentury  |  Regulation

For want of a nail

See Sidebar: Horizons beyond Horizant...
08:00 , Feb 25, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) Dopamine D2 receptor; dopamine D3 receptor Studies in rats identified a hybrid molecule with D2/D3 receptor agonist and iron chelation activities that...
08:00 , Feb 22, 2010 |  BioCentury  |  Regulation

Rat Poisoning

FDA's decision not to approve XenoPort Inc. 's Horizant gabapentin enacarbil to treat restless legs syndrome last week is a puzzling application of the precautionary principle. According to the company and its partner GlaxoSmithKline plc...